Genetic Evidence That New Therapies Targeting Parkinson's Disease May Cause Harm, NorthShore University HealthSystem Research Institute and Mayo Clinic Study

Published: Mar 21, 2013

NorthShore University HealthSystem (NorthShore) and Mayo Clinic researchers have partnered on a study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein -- a gene whose function is involved in the development and progression of Parkinson's disease -- may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinson's disease.

Back to news